

Protein Expr Purif. 2014 Feb;94:79-84.

Production of a defensin-like antifungal protein NFAP from *Neosartorya fischeri* in *Pichia pastoris* and its antifungal activity against filamentous fungal isolates from human infections.

Virágh M¹, Vörös D¹, Kele Z², Kovács L¹, Fizi Á³, Lakatos G⁴, Maróti G⁴, Batta G³, Vágvolgyi C¹, Galgóczy L⁵.

- ¹Department of Microbiology, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged H-6726, Hungary.
- ²Department of Medical Chemistry, Faculty of Medicine, University of Szeged, Dóm tér 8, Szeged H-6720, Hungary.
- ³Department of Organic Chemistry, University of Debrecen, Egyetem tér 1, Debrecen H-4010, Hungary.
- ⁴Institute of Biochemistry, Hungarian Academy of Sciences, Biological Research Centre, Temesvári krt. 62, Szeged H-6726, Hungary.
- ⁵Department of Microbiology, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged H-6726, Hungary. Electronic address: galgoczi@gmail.com.

Abstract

Neosartorya fischeri NRRL 181 isolate secretes a defensin-like antifungal protein (NFAP) which has a remarkable antifungal effect against ascomycetous filamentous fungi. This protein is a promising antifungal agent of biotechnological value; however in spite of the available knowledge of the nature of its 5'-upstream transcriptional regulation elements, the bulk production of NFAP has not been resolved yet. In this study we carried out its heterologous expression in the yeast *Pichia pastoris* and investigated the growth inhibition effect exerted by the heterologous NFAP (hNFAP) on filamentous fungal isolates from human infections compared with what was caused by the native NFAP. *P. pastoris* KM71H transformant strain harboring the pPICZαA plasmid with the mature NFAP encoding gene produced the protein. The final yield of the hNFAP was sixfold compared to the NFAP produced by *N. fischeri* NRRL 181. Based on the signal dispersion of the amide region, it was proven that the hNFAP exists in folded state. The purified hNFAP effectively inhibited the growth of fungal isolates belonging to the *Aspergillus* and to the *Fusarium* genus, but all investigated zygomycetous strain proved to be insusceptible. There was no significant difference between the growth inhibition effect exerted by the native and the heterologous NFAP. These data indicated that *P. pastoris* KM71H can produce the NFAP in an antifungally active folded state. Our results provide a base for further research, e.g., investigation the connection between the protein structure and the antifungal activity using site directed mutagenesis. Copyright © 2013 Elsevier Inc.

KEYWORDS: Antimicrobial susceptibility, Ascomycetes, Clinical fungal isolates, *Neosartorya fischeri* antifungal protein, *Pichia pastoris*, Zygomycetes

PMID: 24269762

Supplement

The increased incidence of severe fungal infections and the fast development of drug resistant filamentous fungi causing mycoses, plant infections or damage of cultural heritages strongly demand for the development of new antifungal strategies. Cysteine-rich antifungal proteins secreted by filamentous Ascomycetes have great potential in these fields. The fact that they (i) have potent antifungal activity against opportunistic human, animal, plant and food-borne pathogenic fungal species [1,2,3], (ii) show no toxic effects on plant and mammalian cells *in vitro* and *in vivo* [2,4,5], (iii) interact synergistically with other antifungal drugs and peptides [3], (iv) are highly stabile [1], and (v) the low cost production render them suitable compounds of commercial preservatives, bio-pesticides and drugs against filamentous fungi [1,2] and offer an alternative, safely applicable solution for the challenges mentioned above.

The *Neosartorya fischeri* antifungal protein (NFAP) (**Fig. 1.**) is a novel representative of the group of cysteine-rich antifungal proteins from Ascomycetes. [6]. NFAP exhibits antifungal activity exclusively against Ascomycetes, it inhibits the germination of spores and the growth of the hyphae causing hyperbranching [6] (**Fig. 2.**). Its antifungal activity is dose-dependent: NFAP exhibits growth retardation at sublethal concentrations; and act fungicidal with increasing concentrations [6,7]. NFAP interferes with the organization of the cell wall, destroys the chitin filaments, and triggers apoptotic-necrotic event through ROS accumulation [7].

References

- [1] Marx F. Small, basic antifungal proteins secreted from filamentous ascomycetes: a comparative study regarding expression, structure, function and potential application. *Appl Microbiol Biotechnol* 2004;65:133-142. DOI 10.1007/s00253-004-1600-z
- [2] Meyer V. A small protein that fights fungi: AFP as a new promising antifungal agent of biotechnological value. *Appl Microbiol Biotechnol* 2008;78:17-28. DOI 10.1007/s00253-007-1291-3
- [3] Galgóczy L, Kovács L, Vágvolgyi Cs. Defensin-like antifungal proteins secreted by filamentous fungi. In: Méndez-Vilas A, editor. *Current Research, Technology and Education Topics in Applied Microbiology and Microbial Biotechnology Vol. 1*, Microbiology Book Series-Number 2, Bajadóz, Spain, Formatex, 2010, p 550-559. ISBN (13): 978-84-614-6195-0, <http://www.formatex.info/microbiology2/550-559.pdf>
- [4] Marx F, Binder U, Leiter É, Pócsi I. The *Penicillium chrysogenum* antifungal protein PAF, a promising tool for the development of new antifungal therapies and fungal cell biology studies. *Cell Mol Life Sci* 2008;65:445-454. DOI 10.1007/s00018-007-7364-8
- [5] Palicz Z, Jenes Á, Gáll T, Miszti-Blasius K, Kollár S, Kovács I, Emri M, Márián T, Leiter É, Pócsi I, Csősz É, Kalló G, Hegedűs Cs, Virág L, Csernoch L, Szentesi P. In vivo application of a small molecular weight antifungal protein of *Penicillium chrysogenum* (PAF). *Toxicol Appl Pharmacol* 2013;269:8-16. DOI 10.1016/j.taap.2013.02.014
- [6] Kovács L, Virágh M, Takó M, Papp T, Vágvolgyi Cs, Galgóczy L. Isolation and characterization of *Neosartorya fischeri* antifungal protein (NFAP). *Peptides* 2011;32:1724-1731. DOI 10.1016/j.peptides.2011.06.022
- [7] Galgóczy L, Kovács L, Karácsony Z, Virágh M, Hamari Zs, Vágvolgyi Cs. Investigation of the antimicrobial effect of *Neosartorya fischeri* antifungal protein (NFAP) after heterologous expression in *Aspergillus nidulans*. *Microbiol-SGM* 2013;159:411-419. DOI 10.1099/mic.0.061119-0

[8] Sali A, Potterton L, Yuan F, van Vlijmen H, Karplus M. Evaluation of comparative protein modelling by MODELLER. *Proteins* 1995;23:318-326. DOI: 10.1002/prot.340230306

[9] Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera—a visualization system for exploratory research and analysis. *J Comput Chem* 2004;25:1605-1612. DOI 10.1002/jcc.20084

Acknowledgement

The research of Á.F., G.B., V.Cs. and L.G. was supported by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TÁMOP 4.2.4.A/2-11-1-2012-0001 'National Excellence Program'. The relating research groups were also supported by the Hungarian Scientific Research Fund (OTKA; grant reference number PD 83355) and by the EU ERC AdG grant "SYMBIOTICS" providing infrastructure and research equipment.

We are grateful for Dr. Florentine Marx (Innsbruck Medical University) for the scientific discussions offered in our projects.




Fig. 1. Putative tertiary structure of the mature NFAP predicted *in silico* by the MODELLER 9.9 and visualized by UCSF Chimera software [8,9]. Domain 1 and 2 is indicated by dark grey and orange red, respectively. Disulfide bridges are marked with yellow lines.




Fig. 2. Morphological changes of *Aspergillus nidulans* FGSC 4A hyphae in the presence of 25 µg/ml NFAP (A) compared to the untreated control (B).